CA2162149A1 - Anticorps pour la p-selectine et leurs utilisations - Google Patents

Anticorps pour la p-selectine et leurs utilisations

Info

Publication number
CA2162149A1
CA2162149A1 CA002162149A CA2162149A CA2162149A1 CA 2162149 A1 CA2162149 A1 CA 2162149A1 CA 002162149 A CA002162149 A CA 002162149A CA 2162149 A CA2162149 A CA 2162149A CA 2162149 A1 CA2162149 A1 CA 2162149A1
Authority
CA
Canada
Prior art keywords
antibodies
selectin
activated
leukocytes
murine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002162149A
Other languages
English (en)
Other versions
CA2162149C (fr
Inventor
Robert W. Chesnut
Margaret J. Polley
James C. Paulson
S. Tarran Jones
Jose W. Saldanha
Mary M. Bendig
Michael Kriegler
Carl Perez
Robert Bayer
Michael Nunn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeres Biomedical Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1993/004274 external-priority patent/WO1993021956A1/fr
Priority claimed from US08/202,047 external-priority patent/US5800815A/en
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US1994/004935 external-priority patent/WO1994025067A1/fr
Publication of CA2162149A1 publication Critical patent/CA2162149A1/fr
Application granted granted Critical
Publication of CA2162149C publication Critical patent/CA2162149C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002162149A 1993-05-04 1994-05-04 Anticorps pour la p-selectine et leurs utilisations Expired - Fee Related CA2162149C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/US1993/004274 WO1993021956A1 (fr) 1992-05-05 1993-05-04 Anticorps contre la p-selectine et leurs emplois
WOPCT/US93/04274 1993-05-04
US5729293A 1993-05-05 1993-05-05
US08/057,292 1993-05-05
US08/202,047 US5800815A (en) 1903-05-05 1994-02-25 Antibodies to P-selectin and their uses
US08/202,047 1994-02-25
PCT/US1994/004935 WO1994025067A1 (fr) 1993-05-04 1994-05-04 Anticorps diriges contre la selectine p et leurs utilisations

Publications (2)

Publication Number Publication Date
CA2162149A1 true CA2162149A1 (fr) 1994-11-10
CA2162149C CA2162149C (fr) 2007-07-10

Family

ID=26736298

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002162149A Expired - Fee Related CA2162149C (fr) 1993-05-04 1994-05-04 Anticorps pour la p-selectine et leurs utilisations

Country Status (8)

Country Link
CN (1) CN1124928A (fr)
CA (1) CA2162149C (fr)
CZ (1) CZ287295A3 (fr)
HU (1) HUT75894A (fr)
NO (1) NO954403L (fr)
NZ (1) NZ266934A (fr)
PL (1) PL311666A1 (fr)
SK (1) SK137795A3 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113952468A (zh) * 2021-09-26 2022-01-21 中国人民解放军空军军医大学 一种治疗心肌缺血再灌注损伤的环孢菌素a纳米药物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28886A1 (es) * 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
AU2011349124B2 (en) * 2010-12-21 2016-09-15 Oklahoma Medical Research Foundation Anti-P-selectin antibodies and methods of their use and identification

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113952468A (zh) * 2021-09-26 2022-01-21 中国人民解放军空军军医大学 一种治疗心肌缺血再灌注损伤的环孢菌素a纳米药物
CN113952468B (zh) * 2021-09-26 2023-07-07 中国人民解放军空军军医大学 一种治疗心肌缺血再灌注损伤的环孢菌素a纳米药物

Also Published As

Publication number Publication date
NZ266934A (en) 1997-07-27
CA2162149C (fr) 2007-07-10
HU9503156D0 (en) 1996-01-29
SK137795A3 (en) 1996-11-06
NO954403L (no) 1996-01-03
NO954403D0 (no) 1995-11-03
PL311666A1 (en) 1996-03-04
CZ287295A3 (en) 1996-05-15
HUT75894A (en) 1997-05-28
CN1124928A (zh) 1996-06-19

Similar Documents

Publication Publication Date Title
AU3608489A (en) Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
CA2182013A1 (fr) Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4
CA2048544A1 (fr) Agent d'embolisation intravasculaire contenant une substance inhibitrice de l'angiogenese
EP1616883A3 (fr) Anticorps dirgés contre VLA-4
AU8072294A (en) Improved visualization of choroidal blood flow and aberrant vascular structures in the eye
FI955261A0 (fi) P-selektiinin vasta-aineita ja niiden käyttö
AU4032989A (en) Method and compositions for the treatment and prevention of septic shock
AU629777B2 (en) Blocking agents of edrf effect or formation for the treatment of shock
AU2371095A (en) Compositions and methods for inhibiting the binding of e-selectin or p-selectin to sialyl-lewisx or sialyl-lewisa
AU4408593A (en) Methods and activator compositions to disinfect lenses
CA2093667A1 (fr) Anticorps monoclonaux murins et leur utilisation
AU674358B2 (en) Novel 1,2-benzoisoxazole derivative or its salt and brain -protecting agent comprising the same
CA2218289A1 (fr) Composes de liaison cd45rb pour prevenir le rejet de greffon
CA2184461A1 (fr) Methode pour empecher la liaison irreguliere des cellules du cristallin humain
IS4181A (is) Fúkósýleruð glýkósíð sem hindra viðloðun baktería
CA2060208A1 (fr) Traitement des plaies
WO1996040743A3 (fr) INHIBITEURS DU FACTEUR Xa
AU3899893A (en) Compositions for the treatment of acute or chronic inflammation
AU6633694A (en) Novel methods and compositions for the treatment of (ras)-activated cancer with heterotypic anti-(raf) antisense oligonucleotides
ITMI930849A0 (it) Procedimento per l'applicazione di interstrati metallici
FR2678604B1 (fr) Composition de verre trouvant application dans le domaine de l'electronique.
CA2139652A1 (fr) Inhibiteurs de la thrombine
CA2174097A1 (fr) Peptides et pseudopeptides a groupe azacycloalkylalcanoyle ayant des proprietes antithrombotiques
BG100863A (en) Fibrin-specifil antibody and its use as an antithrombotic agent
HU9402421D0 (en) 3-alkyloxy-, aryloxy- or arylalkyloxy-benzo [b] thiophene-2-carboxamides as inhibitors of cell adhesion

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed